RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC

An open trial on stomach cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07068529, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Availability of primary tumor tissue from surgery or biopsy that meets submission requirements;

    Inclusion criterion 9

  3. Performance status (ECOG) score ≤ 1;

    Inclusion criterion 5

  4. Known history of other malignancies that have progressed or required treatment within the past 5 years, except for skin basal cell carcinoma and squamous cell carcinoma that have been cured;

    Exclusion criterion 4

    Known history of other malignancies that have progressed or required treatment within the past 5 years, except for skin basal cell carcinoma and squamous cell carcinoma that have been cured;

    Exclusion criterion 15

  5. Pregnant, breastfeeding, or planning to become pregnant within the next year;

    Exclusion criterion 11

    Pregnant, breastfeeding, or planning to become pregnant within the next year;

    Exclusion criterion 19

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07068529, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • **Healthy Controls:**
  • Age ≥ 18 years;
  • Signed informed consent and willingness to participate in the project.

**Colorectal Cancer:**

  • Age ≥ 18 years;
  • Performance status (ECOG) score ≤ 1;
  • Histopathologically confirmed colorectal adenocarcinoma;
  • No family history of hereditary cancer;
  • No prior anti-tumor treatment;
  • Availability of primary tumor tissue from surgery or biopsy that meets submission requirements;
  • Availability of peripheral blood samples that meet submission requirements;
  • Willingness and ability to sign the informed consent form to participate in the study.

Exclusion Criteria:

  • **Healthy Controls:**
  • Individuals at high risk for hereditary colorectal adenocarcinoma, including family members of the following diseases: family history of gastrointestinal tumors, familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC/LS), and Peutz-Jeghers syndrome (P-J syndrome);
  • History of chronic metabolic or inflammatory diseases that are difficult to control, such as hypertension, diabetes, chronic viral hepatitis, and inflammatory bowel disease;
  • Known history of other malignancies that have progressed or required treatment within the past 5 years, except for skin basal cell carcinoma and squamous cell carcinoma that have been cured;
  • History of oral or intravenous use of broad-spectrum antibiotics and probiotics within the past month;
  • Regular use of immunosuppressive drugs within the past 6 months;
  • Long-term use of other medications that may affect metabolism, such as hormones;
  • Inability or unwillingness to cooperate with follow-up visits and related examinations;
  • Inability to eat normally or requiring medications or enemas for bowel movements;
  • Presence of psychiatric disorders or other severe cardiovascular diseases;
  • Pregnant, breastfeeding, or planning to become pregnant within the next year;
  • Currently participating in an interventional clinical study or receiving study treatment that may influence the patient's treatment decision.

**Colorectal Cancer:**

  • A clear family history of hereditary colorectal cancer, such as Lynch syndrome, familial adenomatous polyposis, Peutz-Jeghers syndrome, etc.;
  • Currently participating in an interventional clinical study or receiving study treatment that may influence the patient's treatment decision;
  • Known history of other malignancies that have progressed or required treatment within the past 5 years, except for skin basal cell carcinoma and squamous cell carcinoma that have been cured;
  • History of chronic metabolic or inflammatory diseases that are difficult to control, such as hypertension, diabetes, chronic viral hepatitis, and inflammatory bowel disease;
  • Presence of poorly controlled chronic comorbidities that may affect prognosis;
  • Presence of psychiatric disorders or other severe cardiovascular diseases;
  • Pregnant, breastfeeding, or planning to become pregnant within the next year;
  • Long-term use of medications that may affect metabolism, such as hormones, immunosuppressants, antibiotics, etc.;
  • Any severe and/or uncontrolled medical conditions, as judged by the investigator, that may affect the patient's ability to participate in the study or interfere with study results.

Quoted from ClinicalTrials.gov, NCT07068529, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07068529, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07068529